Molecular study of benign and malignant thyroid nodules

doi:10.16138/j.1673-6087.2023.04.011

Abstract

Abstract:

Objective To establish a next-generation sequencing panel for the molecular diagnosis of thyroid nodules. Methods The panel, named ThyNod Panel, was designed to detect single nucleotide variant(SNV), indel, fusion, copy number variant (CNV) and RNA expression levels in 112 thyroid nodules associated genes, including benign and malignant molecular markers, thyroid differentiation or function genes and cell identity marker genes. Results The ThyNod Panel was successfully constructed and applied, and 856 benign or malignant thyroid nodules were completed sequencing. Totally 676 (79.0%) thyroid nodules were detected mutations. In 627 thyroid nodules with definite pathological diagnosis, 17.6% were benign nodules and 82.4% were malignant ones, in which malignant pathological types included classical papillary carcinoma, follicular variant papillary carcinoma, and medullary carcinoma. The most common mutant genes detected were BRAF (n=426), followed by RET (n=68), RET/PTC fusion (n=68), DICER1 (n=35), telomerase reverse transcriptase (TERT) (n=35), HRAS (n=24), NRAS (n=23), neurotrophin receptor kinase （NTRK3） fusion (n=19), and eukaryotic translation initiation factor 1A, X-chromosomal (EIF1AX) (n=11). The malignant percentage was counted for the detected mutations, and the malignant related variants such as BRAF V600E and RET fusion were higher than 90.0%, while the overall malignant percentage of RAS-like variants was only 18.9%. Conclusions ThyNod Panel can efficiently identify genetic characteristics in thyroid nodules and be applied in the molecular diagnosis of thyroid nodules.

Key words: Thyroid nodules, ThyNod Panel, Target sequencing, Fusion

CLC Number:

R581

LI Haorong, HAN Rulai, YU Danyan, YE Lei. Molecular study of benign and malignant thyroid nodules[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 266-269.

Figures/Tables 1

References 17

[1]	Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms[J]. Endocr Pathol, 2022, 33(1): 27-63. doi: 10.1007/s12022-022-09707-3 pmid: 35288841
[2]	Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules[J]. JAMA, 2015, 313(9): 926-935. doi: 10.1001/jama.2015.0956 pmid: 25734734
[3]	Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies[J]. Nat Rev Endocrinol, 2017, 13(11): 644-660. doi: 10.1038/nrendo.2017.76 pmid: 28707679
[4]	Yoo SK, Song YS, Lee EK, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer[J]. Nat Commun, 2019, 10(1): 2764. doi: 10.1038/s41467-019-10680-5
[5]	Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3): 184-199. doi: 10.1038/nrc3431 pmid: 23429735
[6]	Ye L, Zhou X, Huang F, et al. The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing[J]. Nat Commun, 2017, 8: 15533. doi: 10.1038/ncomms15533 pmid: 28580939
[7]	Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas[J]. Nature, 1993, 365(6447): 649-651. doi: 10.1038/365649a0
[8]	Paschke R. Molecular pathogenesis of nodular goiter[J]. Langenbecks Arch Surg, 2011, 396(8): 1127-1136. doi: 10.1007/s00423-011-0788-5 URL
[9]	Shi X, Sun Y, Shen C, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma[J]. Cell Discov, 2022, 8(1): 120. doi: 10.1038/s41421-022-00479-y pmid: 36344509
[10]	Gupta N, Dasyam AK, Carty SE, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers[J]. J Clin Endocrinol Metab, 2013, 98(5): E914-E922. doi: 10.1210/jc.2012-3396 URL
[11]	Guan H, Toraldo G, Cerda S, et al. Utilities of RAS mutations in preoperative fine needle biopsies for decision making for thyroid nodule management[J]. Thyroid, 2020, 30(4): 536-547. doi: 10.1089/thy.2019.0116 URL
[12]	Marcadis AR, Valderrabano P, Ho AS, et al. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules[J]. Surgery, 2019, 165(1): 17-24. doi: 10.1016/j.surg.2018.04.062 URL
[13]	Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors[J]. Endocr Rev, 2010, 31(4): 578-599. doi: 10.1210/er.2009-0031 pmid: 20605972
[14]	Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study[J]. Lancet Diabetes Endocrinol, 2021, 9(8): 491-501. doi: 10.1016/S2213-8587(21)00120-0 URL
[15]	Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children[J]. N Engl J Med, 2018, 378(8): 731-739. doi: 10.1056/NEJMoa1714448 URL
[16]	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3): 676-690. doi: 10.1016/j.cell.2014.09.050 pmid: 25417114
[17]	中华医学会内分泌学分会中华医学会, 外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)(2023版)[J]. 中华内分泌代谢杂志, 2023, 39(3): 181-226.

基因	恶性	良性	总计
BRAF V600E	336（98.0）	7（2.0）	343
RET融合	27（90.0）	3（10.0）	30
TERT	26（100.0）	0（0.0）	26
NRAS/HRAS/KRAS	8（29.6）	18（66.7）	27
NTRK3融合	14（93.3）	1（6.7）	15
DICER1	1（10.0）	9（90.0）	10
BRAF融合	8（88.9）	1（11.1）	9
EIF1AX	1（11.1）	8（88.9）	9
IGF2BP3融合	0（0.0）	7（100.0）	7
CHEK2	4（66.7）	2（33.3）	6
ALK融合	4（100.0）	0（0.0）	4
TP53	3（100.0）	0（0.0）	3
PIK3CA	3（100.0）	0（0.0）	3
ATM	3（100.0）	0（0.0）	3
EZH1	0（0.0）	4（100.0）	4
SPOP	0（0.0）	4（100.0）	4